LIVIVO - Search results -

Search results

Result 1 - 10 of total 67

Search options

Article ; Online: Huntingtons disease: A new evidence of neurovascular dysfunction.

Campa, Claudio

2020 Volume 416, Page(s) 116994

MeSH term(s)	Chorea ; Humans ; Huntington Disease
Language	English
Publishing date	2020-06-18
Publishing country	Netherlands
Document type	Letter
ZDB-ID	80160-4
ISSN	1878-5883 ; 0022-510X ; 0374-8642
ISSN (online)	1878-5883
ISSN	0022-510X ; 0374-8642
DOI	10.1016/j.jns.2020.116994
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 308: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: New Anti-VEGF Drugs in Ophthalmology.

Campa, Claudio

Current drug targets

2020 Volume 21, Issue 12, Page(s) 1194–1200

Abstract: This review focuses on 5 new anti-VEGF drugs in the advanced stage of clinical development (i.e., phase 3): conbercept, brolucizumab, port delivery system with ranibizumab, abicipar pegol and faricimab. Results of clinical trials and the advantages of ... ...

Abstract	This review focuses on 5 new anti-VEGF drugs in the advanced stage of clinical development (i.e., phase 3): conbercept, brolucizumab, port delivery system with ranibizumab, abicipar pegol and faricimab. Results of clinical trials and the advantages of each drug compared to the available molecules are discussed in detail.
MeSH term(s)	Angiogenesis Inhibitors/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; Clinical Trials, Phase III as Topic ; Eye Diseases/drug therapy ; Humans ; Ophthalmology/methods ; Ranibizumab/administration & dosage ; Ranibizumab/therapeutic use ; Recombinant Fusion Proteins/therapeutic use ; Vascular Endothelial Growth Factor A/antagonists & inhibitors
Chemical Substances	Angiogenesis Inhibitors ; Antibodies, Monoclonal, Humanized ; Recombinant Fusion Proteins ; Vascular Endothelial Growth Factor A ; KH902 fusion protein (1P05PW62F3) ; abicipar pegol (M55Q728KNA) ; brolucizumab (XSZ53G39H5) ; Ranibizumab (ZL1R02VT79)
Language	English
Publishing date	2020-04-28
Publishing country	United Arab Emirates
Document type	Journal Article ; Review
ZDB-ID	2064859-5
ISSN	1873-5592 ; 1389-4501
ISSN (online)	1873-5592
ISSN	1389-4501
DOI	10.2174/1389450121666200428101738
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5578: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A Novel Technique for Scleral Fixation of an Intraocular Telescopic Device.

Mura, Marco / Campa, Claudio / Sarti, Laura / Ciarmatori, Nicolò / Demaria, Davide / Pellegrini, Marco

Ophthalmology. Retina

2023 Volume 7, Issue 10, Page(s) 933–935

MeSH term(s)	Humans ; Lenses, Intraocular ; Sclera/surgery
Language	English
Publishing date	2023-07-16
Publishing country	United States
Document type	Journal Article
ISSN	2468-6530
ISSN (online)	2468-6530
DOI	10.1016/j.oret.2023.07.004
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Anti-Vegf Therapy for Ocular Diseases: Present and Future.

Campa, Claudio / Parodi, Maurizio Battaglia

Current drug targets

2020 Volume 21, Issue 12, Page(s) 1158

MeSH term(s)	Angiogenesis Inhibitors/therapeutic use ; Eye Diseases/drug therapy ; Humans ; Neovascularization, Pathologic ; Vascular Endothelial Growth Factor A/antagonists & inhibitors
Chemical Substances	Angiogenesis Inhibitors ; Vascular Endothelial Growth Factor A
Language	English
Publishing date	2020-09-18
Publishing country	United Arab Emirates
Document type	Editorial ; Introductory Journal Article
ZDB-ID	2064859-5
ISSN	1873-5592 ; 1389-4501
ISSN (online)	1873-5592
ISSN	1389-4501
DOI	10.2174/138945012112200727153907
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5578: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Effect of VEGF and anti-VEGF compounds on retinal pigment epithelium permeability: an in vitro study.

Campa, Claudio

European journal of ophthalmology

2013 Volume 23, Issue 5, Page(s) 690–696

Abstract: Objective: To evaluate the effect of 2 vascular endothelial growth factor (VEGF) isoforms (121 and 165) and 2 anti-VEGF compounds (ranibizumab and pegaptanib sodium) on the permeability of human retinal pigment epithelium (RPE) cells in vitro. : ... ...

Abstract	Objective: To evaluate the effect of 2 vascular endothelial growth factor (VEGF) isoforms (121 and 165) and 2 anti-VEGF compounds (ranibizumab and pegaptanib sodium) on the permeability of human retinal pigment epithelium (RPE) cells in vitro.  Methods: The RPE permeability was assessed on ARPE19 cells grown onto inserts of polytetrafluoroethylene previously treated with ammonia gas plasma. Paracellular permeability to ions was measured by mean of transepithelial electrical resistance (TEER). Permeability to non-ionic molecules was gathered by the amount of fluorescein dextran (FD) passing across the monolayer within 2 hours.  Results: Only VEGF165 applied at the apical side of the monolayer induced a statistically significant decrease of TEER (p<0.001). No changes in TEER were observed when pegaptanib sodium or ranibizumab were apically administered together with VEGF165.  Both VEGF isoforms significantly increased permeability to 4 kDa dextran (p<0.01). Apical administration of ranibizumab or pegaptanib sodium as well as coadministration of pegaptanib sodium with VEGF121 or VEGF165 induced a statistically significant increase of permeability to 4 kDa FD.   Conclusion: Both VEGF isoforms and anti-VEGF compounds exert an effect on human RPE permeability in vitro.
MeSH term(s)	Analysis of Variance ; Angiogenesis Inhibitors/therapeutic use ; Antibodies, Monoclonal, Humanized/pharmacology ; Aptamers, Nucleotide/pharmacology ; Cell Membrane Permeability/drug effects ; Cells, Cultured ; Electric Impedance ; Humans ; Ranibizumab ; Retinal Pigment Epithelium/drug effects ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Vascular Endothelial Growth Factor A/pharmacology
Chemical Substances	Angiogenesis Inhibitors ; Antibodies, Monoclonal, Humanized ; Aptamers, Nucleotide ; VEGFA protein, human ; Vascular Endothelial Growth Factor A ; pegaptanib (2H1PA8H1EN) ; Ranibizumab (ZL1R02VT79)
Language	English
Publishing date	2013-09
Publishing country	Italy
Document type	Journal Article
ZDB-ID	1089461-5
ISSN	1724-6016 ; 1120-6721
ISSN (online)	1724-6016
ISSN	1120-6721
DOI	10.5301/ejo.5000248
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3342: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A novel mutation of BEST1 gene in Best disease.

Campa, Claudio / Parmeggiani, Francesco / Spena, Rossella / Ognibene, Davide / Passerini, Ilaria / Gualandi, Francesca

European journal of ophthalmology

2020 Volume 31, Issue 3, Page(s) NP93–NP95

Abstract: Purpose: To describe a new genetic variation of BEST1 gene in Best vitelliform macular dystrophy.: Methods: A patient with bilateral multiple retinal yellowish lesions at the posterior pole underwent fluorescein angiography, fundus autofluorescence, ... ...

Abstract	Purpose: To describe a new genetic variation of BEST1 gene in Best vitelliform macular dystrophy. Methods: A patient with bilateral multiple retinal yellowish lesions at the posterior pole underwent fluorescein angiography, fundus autofluorescence, optical coherence tomography, electrooculogram and blood sample for genetic testing. Results: A diagnosis of a Best vitelliform macular dystrophy was made. Heterozygous mutation c.76G > A (p.Gly26Ser) in exon 2 of the BEST1 gene was found. Conclusion: These findings contribute to expand the mutation spectrum of BEST1 gene.
MeSH term(s)	Bestrophins/genetics ; Chloride Channels/genetics ; Electrooculography ; Eye Proteins/genetics ; Fluorescein Angiography ; Humans ; Mutation ; Tomography, Optical Coherence ; Vitelliform Macular Dystrophy/diagnosis ; Vitelliform Macular Dystrophy/genetics
Chemical Substances	BEST1 protein, human ; Bestrophins ; Chloride Channels ; Eye Proteins
Language	English
Publishing date	2020-04-22
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	1089461-5
ISSN	1724-6016 ; 1120-6721
ISSN (online)	1724-6016
ISSN	1120-6721
DOI	10.1177/1120672120920536
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3342: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Application of Artificial Intelligence in Targeting Retinal Diseases.

Sorrentino, Francesco Saverio / Jurman, Giuseppe / De Nadai, Katia / Campa, Claudio / Furlanello, Cesare / Parmeggiani, Francesco

Current drug targets

2020 Volume 21, Issue 12, Page(s) 1208–1215

Abstract: Retinal diseases affect an increasing number of patients worldwide because of the aging population. Request for diagnostic imaging in ophthalmology is ramping up, while the number of specialists keeps shrinking. Cutting-edge technology embedding ... ...

Abstract	Retinal diseases affect an increasing number of patients worldwide because of the aging population. Request for diagnostic imaging in ophthalmology is ramping up, while the number of specialists keeps shrinking. Cutting-edge technology embedding artificial intelligence (AI) algorithms are thus advocated to help ophthalmologists perform their clinical tasks as well as to provide a source for the advancement of novel biomarkers. In particular, optical coherence tomography (OCT) evaluation of the retina can be augmented by algorithms based on machine learning and deep learning to early detect, qualitatively localize and quantitatively measure epi/intra/subretinal abnormalities or pathological features of macular or neural diseases. In this paper, we discuss the use of AI to facilitate efficacy and accuracy of retinal imaging in those diseases increasingly treated by intravitreal vascular endothelial growth factor (VEGF) inhibitors (i.e. anti-VEGF drugs), also including integration and interpretation features in the process. We review recent advances by AI in diabetic retinopathy, age-related macular degeneration, and retinopathy of prematurity that envision a potentially key role of highly automated systems in screening, early diagnosis, grading and individualized therapy. We discuss benefits and critical aspects of automating the evaluation of disease activity, recurrences, the timing of retreatment and therapeutically potential novel targets in ophthalmology. The impact of massive employment of AI to optimize clinical assistance and encourage tailored therapies for distinct patterns of retinal diseases is also discussed.
MeSH term(s)	Angiogenesis Inhibitors/therapeutic use ; Artificial Intelligence ; Diabetic Retinopathy/diagnostic imaging ; Diabetic Retinopathy/drug therapy ; Humans ; Macular Degeneration/diagnostic imaging ; Macular Degeneration/drug therapy ; Retinopathy of Prematurity/diagnostic imaging ; Retinopathy of Prematurity/drug therapy ; Tomography, Optical Coherence ; Vascular Endothelial Growth Factor A/antagonists & inhibitors
Chemical Substances	Angiogenesis Inhibitors ; Vascular Endothelial Growth Factor A
Language	English
Publishing date	2020-08-02
Publishing country	United Arab Emirates
Document type	Journal Article ; Review
ZDB-ID	2064859-5
ISSN	1873-5592 ; 1389-4501
ISSN (online)	1873-5592
ISSN	1389-4501
DOI	10.2174/1389450121666200708120646
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5578: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Comparison of the Efficacy of Dexamethasone, Nepafenac, and Bromfenac for Preventing Pseudophakic Cystoid Macular Edema: an Open-label, Prospective, Randomized Controlled Trial.

Campa, Claudio / Salsini, Giulia / Perri, Paolo

Current eye research

2017 Volume 43, Issue 3, Page(s) 362–367

Abstract: Purpose: To evaluate the incidence of pseudophakic cystoid macular edema (PCMO) in patients treated with corticosteroids alone or in combination with bromfenac or nepafenac eyedrops after uneventful cataract surgery.: Materials and methods: ... ...

Abstract	Purpose: To evaluate the incidence of pseudophakic cystoid macular edema (PCMO) in patients treated with corticosteroids alone or in combination with bromfenac or nepafenac eyedrops after uneventful cataract surgery. Materials and methods: Prospective, randomized, open-label, placebo-controlled clinical trial. Patients who underwent routine cataract surgery with intraocular lens (IOL) implant were randomly divided into three groups receiving either bromfenac or nepafenac in association with dexamethasone or dexamethasone alone (control group) postoperatively. Best-corrected visual acuity (BCVA) measurement, slit lamp and fundus examination and optical coherence tomography (OCT) were performed preoperatively, 1 and 5 weeks after surgery. Primary outcome was defined as patients (%) in whom macular edema developed within 5 weeks after cataract surgery; secondary end points were patients (%) with BCVA improvement from pre-op through 5 weeks after surgery and corneal toxicity. Results: A total of 144 patients completed the study, 48 for each group. In all groups, mean central subfield thickness at OCT increased significantly 5 weeks after surgery (p < 0.01). However, at this time point, four patients (8.3%) of the control group and none in nepafenac and bromfenac groups developed PCMO (p = 0.016). Compared with baseline, mean BCVA significantly improved both at 1 and 5 weeks in all groups (p < 0.01). At 1 week, the nepafenac group showed a mean BCVA significantly lower compared with both the control (p = 0.038) and bromfenac group (p = 0.002). Conclusions: Co-administration of nepafenac or bromfenac and steroids in patients who underwent routine cataract surgery is associated with a lower incidence of PCMO compared with steroid monotherapy.
MeSH term(s)	Aged ; Anti-Inflammatory Agents, Non-Steroidal/administration & dosage ; Benzeneacetamides/administration & dosage ; Benzophenones/administration & dosage ; Bromobenzenes/administration & dosage ; Cataract Extraction ; Dexamethasone/administration & dosage ; Dose-Response Relationship, Drug ; Drug Therapy, Combination ; Female ; Fluorescein Angiography ; Follow-Up Studies ; Fundus Oculi ; Glucocorticoids/administration & dosage ; Humans ; Macula Lutea/pathology ; Macular Edema/diagnosis ; Macular Edema/etiology ; Macular Edema/prevention & control ; Male ; Ophthalmic Solutions/administration & dosage ; Phenylacetates/administration & dosage ; Prospective Studies ; Pseudophakia/complications ; Tomography, Optical Coherence ; Treatment Outcome ; Visual Acuity
Chemical Substances	Anti-Inflammatory Agents, Non-Steroidal ; Benzeneacetamides ; Benzophenones ; Bromobenzenes ; Glucocorticoids ; Ophthalmic Solutions ; Phenylacetates ; nepafenac (0J9L7J6V8C) ; Dexamethasone (7S5I7G3JQL) ; bromfenac (864P0921DW)
Language	English
Publishing date	2017-11-09
Publishing country	England
Document type	Journal Article ; Randomized Controlled Trial
ZDB-ID	82079-9
ISSN	1460-2202 ; 0271-3683
ISSN (online)	1460-2202
ISSN	0271-3683
DOI	10.1080/02713683.2017.1396615
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1775: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Two-year visual results for older asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization.

Campa, Claudio / Harding, Simon P

American journal of ophthalmology

2010 Volume 149, Issue 6, Page(s) 1014–5; author reply 1015–6

MeSH term(s)	Aged ; Angiogenesis Inhibitors/therapeutic use ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized ; Asian Continental Ancestry Group/ethnology ; Bevacizumab ; Choroidal Neovascularization/drug therapy ; Choroidal Neovascularization/ethnology ; Choroidal Neovascularization/physiopathology ; Female ; Fluorescein Angiography ; Humans ; Injections ; Intraocular Pressure ; Japan/epidemiology ; Middle Aged ; Myopia, Degenerative/drug therapy ; Myopia, Degenerative/ethnology ; Myopia, Degenerative/physiopathology ; Photochemotherapy ; Retreatment ; Tomography, Optical Coherence ; Treatment Outcome ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Visual Acuity/physiology ; Vitreous Body ; Women's Health
Chemical Substances	Angiogenesis Inhibitors ; Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Vascular Endothelial Growth Factor A ; Bevacizumab (2S9ZZM9Q9V)
Language	English
Publishing date	2010-06
Publishing country	United States
Document type	Comment ; Letter
ZDB-ID	80030-2
ISSN	1879-1891 ; 0002-9394
ISSN (online)	1879-1891
ISSN	0002-9394
DOI	10.1016/j.ajo.2010.02.021
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ul I Zs.39: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Guardians' Perceptions of Cats' Welfare and Behavior Regarding Visiting Veterinary Clinics.

Mariti, Chiara / Bowen, Jonathan E / Campa, Sonia / Grebe, Gabriele / Sighieri, Claudio / Gazzano, Angelo

Journal of applied animal welfare science : JAAWS

2016 Volume 19, Issue 4, Page(s) 375–384

Abstract: To assess the welfare of cats at the veterinary clinic and how caregivers and veterinarians affect it, a survey of Italian cat guardians (n = 1,111) was conducted using a 28-item multichoice questionnaire. Most cats showed impaired welfare during all ... ...

Abstract	To assess the welfare of cats at the veterinary clinic and how caregivers and veterinarians affect it, a survey of Italian cat guardians (n = 1,111) was conducted using a 28-item multichoice questionnaire. Most cats showed impaired welfare during all stages of a clinic visit: before entering, in the waiting room, moving to the examination room, on the examination table, and after returning home. A relationship was found between welfare states in each stage. Stress worsened with further experience and had negative effects on traveling and handling in other situations. Restraint, pain, and anxiety led to aggression toward vets and guardians. Guardians showed a positive attitude toward their cats' health and welfare, and the veterinarians' behavior toward the cats was a reason for changing the veterinarian. One in 10 veterinarians examined the cat immediately, without stroking, talking, or offering food. However, the use of food was effective only if cats were not already stressed. Educating guardians and veterinarians to minimize stress during every stage of a clinic visit is the best approach to improving welfare for cats visiting the clinic.
Language	English
Publishing date	2016-10
Publishing country	England
Document type	Journal Article
ISSN	1532-7604
ISSN (online)	1532-7604
DOI	10.1080/10888705.2016.1173548
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED